» Articles » PMID: 17652313

Estimating Pulmonary Artery Pressures by Echocardiography in Patients with Emphysema

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2007 Jul 27
PMID 17652313
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

In patients with emphysema being evaluated for lung volume reduction surgery, Doppler echocardiography has been used to screen for pulmonary hypertension as an indicator of increased peri-operative risk. To determine the accuracy of this test, the present authors compared the results of right heart catheterisations and Doppler echocardiograms in 163 patients participating in the cardiovascular substudy of the National Emphysema Treatment Trial. Substudy patients had both catheterisation and Doppler echocardiography performed before and after randomisation. In 74 paired catheterisations and echocardiograms carried out on 63 patients, the mean values of invasively measured pulmonary artery systolic pressures and the estimated right ventricular systolic pressures were similar. However, using the World Health Organization's definitions of pulmonary hypertension, echocardiography had a sensitivity of 60%, specificity of 74%, positive predictive value of 68% and a negative predictive value of 67% compared with the invasive measurement. Bland-Altman analysis revealed a bias of 0.37 kPa with 95% limits of agreement from -2.5-3.2 kPa. In patients with severe emphysema, echocardiographic estimates of pulmonary artery pressures correlate very weakly with right heart catheterisations, and the test characteristics (e.g. sensitivity, specificity, etc.) of echocardiographic assessments are poor.

Citing Articles

Prognosis of pulmonary hypertension in patients with hypertrophic cardiomyopathy: A multicenter propensity score matching study.

Ma H, Xu F, Liu L, Kong H, Luo R, Liu M Int J Cardiol Heart Vasc. 2025; 56:101605.

PMID: 39897413 PMC: 11783049. DOI: 10.1016/j.ijcha.2025.101605.


The extracellular CIRP as a predictive marker for the endothelial dysfunction in chronic obstructive pulmonary disease combined with pulmonary hypertension.

Yao Y, Jiang H, Xu D, Zhang B, Yao F, Guo W BMC Pulm Med. 2024; 24(1):615.

PMID: 39695535 PMC: 11656910. DOI: 10.1186/s12890-024-03416-9.


Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.

Vitulo P, Piccari L, Wort S, Shlobin O, Kovacs G, Vizza C Pulm Circ. 2024; 14(4):e70005.

PMID: 39659477 PMC: 11629413. DOI: 10.1002/pul2.70005.


Cluster analysis identifies novel real-world lung disease-pulmonary hypertension subphenotypes: implications for treatment response.

Johnson S, Wang R, Winter M, Gillmeyer K, Zeder K, Klings E ERJ Open Res. 2024; 10(3).

PMID: 38770008 PMC: 11103711. DOI: 10.1183/23120541.00959-2023.


Risk factors associated with pulmonary hypertension in patients with active tuberculosis and tuberculous destroyed lung: a retrospective study.

Liu W, Xu Y, Yang L, Zhan S, Pang K, Lin H Sci Rep. 2024; 14(1):10108.

PMID: 38698005 PMC: 11066008. DOI: 10.1038/s41598-024-59679-z.